National Cancer Institute researchers show 6-base sequencing has the potential to transform liquid biopsy utility in informing clinical decisions without parallel tissue samples
6-base ctDNA 5mC/5hmC methylomics and clonal reconstruction infer tumour transcription and resistance phenotypes in metastatic prostate cancer